NCT06663852Completed
ML Decision Model for G-NEC Adjuvant Therapy
Machine Learning-Based Decision Model for Optimal Adjuvant Therapy in Primary Gastric Neuroendocrine Carcinoma: a National Real-World Evidence Study
Source: ClinicalTrials.gov · Last updated 27 Nov 2024
Brief summary (registry, in English)
Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis. Due to its rarity, there is limited data and no established consensus on the optimal postoperative adjuvant therapy, making treatment decisions challenging for healthcare providers. This study is a retrospective analysis focusing on evaluating survival rates, identifying prognostic factors, and formulating treatment recommendations for patients with G-NEC. By analyzing real-world clinical data, we aim to better understand the factors that influence patient outcomes and to develop evidence-based strategies for improving survival. Our goal is to provide clinicians with valuable insights and tools to make more informed treatment decisions, ultimately enhancing the quality of care and outcomes for patients with this challenging disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1505 (actual)
- First submitted
- 26 Oct 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Chang-Ming Huang, Prof.
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT06663852
What you commit to
- Study type: Observational
- Participants enrolled: 1505
- From 1 Jan 2024 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (2) treatment with endoscopic submucosal dissection or endoscopic mucosal resection or thoracotomy;
- (3) incomplete clinical data (including pathological, adjuvant chemotherapy, and follow-up information);
Other illness
- (1) history of other malignant neoplasms;
Other
- (4) receipt of alternative adjuvant treatment regimens;
- (5) death within 30 days postoperatively.
Who the study is looking for
- (1) patients who underwent radical surgery without any neoadjuvant therapy;
- (2) pathology confirmed NEC or mixed adenoneuroendocrine carcinoma (MANEC).
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.